Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital

28 Oct 2020

Abstract excerpt

-methylguanine-DNA methyltransferase (MGMT) promoter methylation status has been considered a prognostic factor in newly diagnosed glioblastoma (GBM). In this study, we evaluated the prognostic and predictive value of MGMT promoter methylation in patients with glioblastoma in Donostia Hospital. Surprisingly, methylation of MGMT promoter did not predict response to temozolomide in patients with glioblastoma in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33116181
DOI: 10.1038/s41598-020-75477-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia HospitalPMID 33116181Read ↗

The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.Semantic proximity Read ↗

Personalized treatment strategies in glioblastoma: MGMT promoter methylation statusSemantic proximity Read ↗

MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational StudySemantic proximity Read ↗

Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: A Portuguese multicentre studySemantic proximity Read ↗

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary GlioblastomaSemantic proximity Read ↗

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challengesSemantic proximity Read ↗

Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatmentSemantic proximity Read ↗

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelSemantic proximity Read ↗

MGMT Promoter Methylation: Prognostication beyond Treatment ResponseSemantic proximity Read ↗

Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort studySemantic proximity Read ↗

Correlation of Clinical Features and Methylation Status of MGMT Gene Promoter in GlioblastomasSemantic proximity Read ↗

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.